IP Library Granted Patent US 9,186,321
Granted Patent B2
US 9,186,321 · App. 14/363,245 · Granted Nov 17, 2015

Oral spray formulations and methods for administration of sildenafil

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,186,321
App. No.
14/363,245
Granted
Nov 17, 2015
Kind
B2
Abstract

The present disclosure is directed to chemically-stable and pharmaceutically acceptable sildenafil oral spray formulations for the treatment of diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction.

Claims (19)

1. A method of treating pulmonary arterial hypertension and/or selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction comprising administering to a subject in need thereof an oral spray formulation comprising a sildenafil base or a pharmaceutically acceptable salt thereof, wherein the pH of the formulation is 1.5 to 2.4.

2. The method of claim 1 , wherein the sildenafil base or a pharmaceutically acceptable salt thereof is present in an amount of 6% to 14% w/v of the formulation.

3. The method of claim 2 , wherein the sildenafil base is present in an amount of 8.31% w/v of the formulation.

4. The method of claim 1 , wherein the sildenafil salt is present in an amount of 10% to 12% w/v of the formulation.

5. The method of claim 4 , wherein the sildenafil salt is present in an amount of 11.67% w/v of the formulation.

6. The method of claim 4 , wherein the sildenafil salt is sildenafil citrate.

7. The method of claim 1 , wherein the formulation further comprises a polar solvent.

8. The method of claim 7 , wherein the polar solvent comprises propylene glycol and ethyl alcohol.

9. The method of claim 8 , wherein the ratio of propylene glycol:ethyl alcohol is 70:30% v/v, 65:35% v/v, 62.5:37.5% v/v, 60:40% v/v, 55:45% v/v or 50:50 v/v.

10. The method of claim 1 , wherein the formulation further comprises a pH-adjusting agent, wherein the pH-adjusting agent is an acidifying agent, an alkalizing agent, or a combination thereof.

11. The method of claim 10 , wherein the acidifying agent is hydrochloric acid (HCl).

12. The method of claim 10 , wherein the alkalizing agent is sodium hydroxide (NaOH).

13. The method of claim 1 , wherein the formulation further comprises a taste-masking agent, a flavoring agent, or a combination thereof.

14. The method of claim 13 , wherein the taste-masking agent or the flavoring agent is a sweetener.

15. The method of claim 13 , wherein the taste-masking agent or the flavoring agent is a fruit flavor, a chocolate flavor, or a combination thereof.

16. The method of claim 14 , wherein the sweetener is sucralose.

17. The method of claim 1 , wherein the formulation further comprises a pharmaceutically acceptable excipient, a carrier, or a combination thereof.

18. The method of claim 1 , wherein the amount of sildenafil administered per spray is between about 10 mg and about 30 mg.

19. The method of claim 1 , wherein the pH of the formulation is 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, or 2.4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2014
From: BERGSTROM, DAVID; OPAWALE, FOYE
To: NOVADEL PHARMA, INC.
Reel/Frame 033456/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2014
From: NOVADEL PHARMA, INC.
To: SUDA LTD.
Reel/Frame 033456/0219 →